

Supplemental Online Content

Frimodt-Møller EK, Vittinghoff E, Kaur G, Biering-Sørensen T, Soliman EZ, Marcus GM. Association between intensive vs standard blood pressure control and incident left ventricular conduction disease: a post hoc analysis of the SPRINT randomized clinical trial. *JAMA Cardiol*. Published online May 3, 2023.
doi:10.1001/jamacardio.2023.0845

eMethods. Definition of comorbidities

eTable 1. Electrocardiographic Findings by Minnesota codes

eTable 2. Type of Incident Left-Ventricular Conduction Disease First Detected According to Randomization Assignment Group

eTable 3. Risk of Left-Ventricular Conduction Disease or Incident Ventricular Pacing in the Intensive Treatment Group Compared with the Standard Treatment Group

eTable 4. Risk of Left-Ventricular Conduction Disease in the Intensive Treatment Group Compared with Standard Treatment Group when Adjusting for Time-Updated Myocardial Infarction and Congestive Heart Failure

eTable 5. Competing Risk Regression with All-Cause Death as a Competing Risk

eTable 6. Baseline Characteristics Associated with Incident Left Ventricular Conduction Disease in Unadjusted Models

eFigure 1. Study Population

eFigure 2. Interaction Analyses

eFigure 3. Blood Pressure Control Group and Baseline Characteristics Associated with Incident Left-Ventricular Conduction Disease After Multivariable Adjustment

This supplemental material has been provided by the authors to give readers additional information about their work.

30 **Supplemental Methods**

31 Definition of comorbidities

32 Clinical or subclinical cardiovascular disease included one or more of the following: (a) previous
33 myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, carotid
34 endarterectomy, carotid stenting, (b) peripheral artery disease with revascularization, (c) acute
35 coronary syndrome with or without resting ECG changes, ECG changes on a graded exercise test,
36 or positive cardiac imaging study, (d) at least a 50% diameter stenosis of a coronary, carotid, or
37 lower extremity artery, (e) abdominal aortic aneurysm ≥ 5 cm with or without repair, (f) coronary
38 artery calcium score ≥ 400 Agatston units within the past 2 years, (g) ankle branchial index ≤ 0.9
39 within the past 2 years, or (h) left ventricular hypertrophy by ECG, echocardiogram report, or other
40 cardiac imaging procedure report within the past 2 years. Atrial fibrillation was defined by its
41 presence on baseline ECG or self-reported. History of congestive heart failure was self-reported.

42

43 Adjudication of incident myocardial infarction and heart failure (referred in the context as
44 congestive heart failure, or CHF) for time-updated sensitivity analyses:

45 Myocardial infarction (MI), defined as the death of part of the myocardium due to an occlusion of a
46 coronary artery from any cause, including spasm, embolus, thrombus or rupture of a
47 plaque. SPRINT used standard case definitions for both fatal and nonfatal MI based
48 on the combination of symptoms, elevation in biomarkers, and/or ECG findings. The
49 algorithm for classifying MI includes elements of the clinical presentation (signs and
50 symptoms), results of cardiac biomarker determinations, and ECG readings. The definition
51 includes MI that occurred during surgery/procedure and MI aborted by thrombolytic
52 therapy or procedure. SPRINT adjudicators were guided by specific, pre-specified

53 definitions and operational rules. MI was ascertained both from adjudication of hospital records for
54 clinical events and also from the finding of new significant Q waves from the standardized
55 interpretation of the study visit-obtained ECG (silent or unrecognized MI).

56 Heart Failure (HF) was defined as hospitalization, or emergency department visit requiring
57 treatment with infusion therapy for a clinical syndrome that presents with multiple signs and
58 symptoms consistent with cardiac decompensation/inadequate cardiac pump function.

59 Adjudication will use the ARIC study adjudication system (Rosamond and others, 2009).

60 The SPRINT HF outcome included definite or possible acute decompensation,

61 The identification and classification of HF cases relied on multiple pieces of key clinical data as
62 well as adjudicators' clinical judgment, guided by specific, pre-specified definitions and operational
63 rules. For participants with advanced CKD with or without chronic dialysis, the ascertainment
64 of HF can be particularly difficult, since the fluid overload can be purely the consequence
65 of fluid retention by the kidney or absence of kidneys. Under these circumstances, the
66 adjudicators used their best judgment, utilizing all available information.

67 **eTable 1. Electrocardiographic Findings by Minnesota codes**

Electrocardiographic finding	Minnesota code
Left anterior fascicular block	7-7
Left bundle branch block	7-1-1, 7-1-2
Intraventricular conduction delay	7-4
Right bundle branch block	7-2-1, 7-2-2
Ventricular pacemaker	6-8
Ventricular pre-excitation	6-4-1, 6-4-2
Left posterior fascicular block*	QRS axis between 90° and 180° and a QRS duration of less than 0.12 seconds in the absence of right ventricular hypertrophy, lateral myocardial infarction, ventricular pre-excitation, left bundle branch block, and pacemaker on the ECG.

68

69 *As left posterior fascicular block (LPFB) was not part of the Minnesota classification, the presence
 70 of LPFB was defined in accordance with previous literature.

71

72

73 **eTable 2. Type of Incident Left-Ventricular Conduction Disease First Detected According to**
 74 **Randomization Assignment Group**

Type of first incident left ventricular conduction disease	Standard treatment N=3,918	Intensive treatment N=3,956
Left anterior fascicular block	34	30
Left posterior fascicular block	1	0
Left bundle branch block	32	25
Intraventricular conduction delay	49	32

75

76

77 **eTable 3. Risk of Left-Ventricular Conduction Disease or Incident Ventricular Pacing in the**
 78 **Intensive Treatment Group Compared with the Standard Treatment Group**

Outcome	Number of events	Model	Hazard ratio (95% CI)	P value
Left-ventricular conduction disease or new ventricular pacing	275	Unadjusted	0.79 (0.62-0.99)	0.047
		Adjusted	0.77 (0.60-0.98)	0.031

79 Adjusted models included age, sex, race, clinical or subclinical cardiovascular disease, congestive
 80 heart failure, and chronic kidney disease.

81

82 **eTable 4. Risk of Left-Ventricular Conduction Disease in the Intensive Treatment Group**
 83 **Compared with Standard Treatment Group when Adjusting for Time-Updated Myocardial**
 84 **Infarction and Congestive Heart Failure**

Time-updated variable (n of events post-intervention)	Adjusted Hazard Ratio (95% CI)	P value
Myocardial infarction (33)*	0.74 (0.56-0.98)	0.04
Congestive heart failure (53)*	0.74 (0.56-0.98)	0.04

85 *None of these events occurred before a left-ventricular conduction disease diagnosis.
 86 Models were adjusted for age, sex, race, clinical or subclinical cardiovascular disease, prevalent
 87 congestive heart failure, and chronic kidney disease.

88

89 **eTable 5. Competing Risk Regression with All-Cause Death as a Competing Risk**

Outcome	Number of events	Model	Subdistribution hazard ratio (95% CI)	P value
Left-ventricular conduction disease	203	Unadjusted	0.76 (0.57-0.99)	0.048
		Adjusted	0.75 (0.56-0.99)	0.042
Right bundle branch block	184	Unadjusted	0.96 (0.72-1.29)	0.80
		Adjusted	0.96 (0.72-1.28)	0.79

90 Risk of incident left-ventricular conduction disease and right bundle branch block when considering
 91 all-cause death as a competing risk.

92 Number of all-cause deaths, n = 211.

93 Adjusted models included age, sex, race, clinical or subclinical cardiovascular disease, congestive
 94 heart failure, and chronic kidney disease.

95

96 **eTable 6. Baseline Characteristics Associated with Incident Left Ventricular Conduction**
 97 **Disease in Unadjusted Models.**

Characteristic	Hazard ratio (95% CI)	P-value
Intensive BP control	0.75 (0.57-0.99)	0.046
Age^a	1.47 (1.26-1.70)	<0.001
Male sex	2.33 (1.65-3.29)	<0.001
Race		
White	Reference	
Non-white	0.63 (0.46-0.86)	0.004
Ethnicity		
Hispanic	Reference	
Non-Hispanic	0.93 (0.61-1.42)	0.73
Body mass index^b	1.18 (0.88-1.59)	0.27
Smoking		
Never	Reference	
Ever smoked	1.25 (0.96-1.63)	0.10
Vigorous activity		
None	Reference	
1-3 times/month	0.72 (0.45-1.13)	0.16
1 time/month	0.68 (0.39-1.17)	0.16
2-4 times/week	1.10 (0.73-1.45)	0.86
>5 times/week	0.80 (0.50-1.29)	0.36
Aspirin use	1.16 (0.88-1.53)	0.29
Clinical or subclinical cardiovascular disease	1.81 (1.33-2.46)	<0.001
Atrial fibrillation	2.12 (0.87-5.16)	0.10
Congestive heart failure	2.03 (1.13-3.64)	0.017
Chronic kidney failure	1.38 (1.03-1.85)	0.029

98 ^a Interpreted as a hazard for every 10-year increase

99 ^b Interpreted as a hazard for every 10 kg/m² increase

100

101 **Figure legends:**

102 **eFigure 1. CONSORT Flow Diagram**

103 Inclusions and exclusions of the participants in the present study.

104 **ECG:** electrocardiogram, **SPRINT:** Systolic Blood Pressure Intervention Trial.

105

106 **eFigure 2. Interaction Analyses**

107 Interactions between randomization assignment, listed covariates, and the risk of incident left-
108 ventricular conduction disease. The models were adjusted for age, sex, race, clinical or subclinical
109 cardiovascular disease, congestive heart failure, and chronic kidney disease.

110 ^a Age is stratified by the mean age in study cohort.

111 Circles represent hazard ratios and error bars denote 95% confidence intervals.

112 **CVD:** Cardiovascular disease (see text for criteria)

113

114 **eFigure 3. Blood Pressure Control Group and Baseline Characteristics Associated with**
115 **Incident Left-Ventricular Conduction Disease After Multivariable Adjustment**

116 Baseline characteristics associated with incident left-ventricular conduction disease. Multivariable
117 adjustment included treatment group, age, sex, race, clinical or subclinical cardiovascular disease,
118 congestive heart failure, and chronic kidney disease.

119 ^a Interpreted as a hazard for every 10-year increase

120 ^b Interpreted as a hazard for every 10 kg/m²-increase

121 Blue circles represent hazard ratios and error bars denote 95% confidence intervals.


122

123 **CVD:** Cardiovascular disease

124

125

126 **eFigure 1. CONSORT Flow Diagram**




127

128 Inclusions and exclusions of the participants in the present study.

129 **BP:** blood pressure, **ECG:** electrocardiogram

130 **eFigure 2. Interaction Analyses**



131

132

133 Interactions between randomization assignment, listed covariates, and the risk of incident left-
 134 ventricular conduction disease. The models were adjusted for age, sex, race, clinical or subclinical
 135 cardiovascular disease, congestive heart failure, and chronic kidney disease.


136 ^a Age is stratified by the mean age in study cohort.

137 Circles represent hazard ratios and error bars denote 95% confidence intervals.

138 **CVD:** Cardiovascular disease (see text for criteria).

139

140 **eFigure 3. Blood Pressure Control Group and Baseline Characteristics Associated with**
 141 **Incident Left-Ventricular Conduction Disease After Multivariable Adjustment**



142

143

144 Baseline characteristics associated with incident left-ventricular conduction disease. Multivariable
 145 adjustment included treatment group, age, sex, race, clinical or subclinical cardiovascular disease,
 146 congestive heart failure, and chronic kidney disease.

147 ^a Interpreted as a hazard for every 10-year increase

148 ^b Interpreted as a hazard for every 10 kg/m²-increase

149 Blue circles represent hazard ratios and error bars denote 95% confidence intervals.

150

151 **CVD:** Cardiovascular disease

152

153